Development of proteomic methods for analysis of cerebrospinal fluid
Proteomic analysis of body fluids represents a real challenge due to the very large dynamic range of protein concentrations: basically, the vast majority of the protein content is represented by only one or a few proteins, which hinder the detection of low-abundant species. We have been involved in the testing of the Proteominer technology, which represents a powerful tool to go much deeper into the proteome characterization.
Proteomic analysis of CSF samples
|
 |
 |
References
Mouton-Barbosa et al (2010) In-depth exploration of cerebrospinal fluid by combining peptide ligand library treatment and label-free protein quantification. Molecular & cellular proteomics : MCP 9, 1006-1021.
Clinical projects
- Identification of biomarkers of obstructive nephropathy, a kidney pathology of newborn infants (Collaboration JP Schanstra and JL Bascands, Inserm, Toulouse)
- Identification biomarkers of abdominal aortic aneurysms in plasma-derived microvesicles (Collaboration JL Martin-Ventura, Universidad Autonoma de Madrid)
- Biomarkers for CNS relapse of diffuse large B cell lymphomas (Collaboration C. Thieblemont, Hôpital Saint-Louis, Paris)
Identification of obstructive nephropathy biomarkers in urine
References
Lacroix C et al (2014) Label-free quantitative urinary proteomics identifies the arginase pathway as a new player in congenital obstructive nephropathy. Molecular & cellular proteomics 13, 3421-3434.
Martinez-Pinna R et al (2014) Label-free quantitative proteomic analysis of human plasma-derived microvesicles to find protein signatures of abdominal aortic aneurysms. Proteomics. Clinical applications 8, 620-625.